RG
NBIX icon

Redmile Group’s Neurocrine Biosciences NBIX Stock Holding History

Redmile Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,740
Closed -$247K – 72
2019
Q3 		$247K Hold
2,740
– – 0.01% 67
2019
Q2 		$231K Buy
+2,740
New +$225K 0.01% 77
2017
Q4 		– Sell
-6,640
Closed -$407K – 77
2017
Q3 		$407K Hold
6,640
– – 0.02% 59
2017
Q2 		$305K Sell
6,640
-615,705
-99% -$29.9M 0.02% 57
2017
Q1 		$26.9M Buy
+622,345
New +$26.7M 1.75% 22
2013
Q3 		– Sell
-580,500
Closed -$7.77M – 57
2013
Q2 		$7.77M Buy
+580,500
New +$7.13M 1.4% 29

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return